INmune Bio stock falls 3.61 percent as October catalysts approach
Published on 10/07/2026 at 02:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
INmune Bio stock (ISIN US45782T1051) was last at USD 1.87 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 3.61 percent for the session. The company is preparing for a series of investor and clinical-development updates in October.
Maxim summit sets the next date
According to an October 6 release from INmune Bio, the company will attend the Maxim Growth Summit from October 12 to October 14, 2026. Chief Executive Officer David Moss is scheduled to present on an immunology and inflammation therapies panel during the event.
The summit gives INmune Bio a near-term platform to discuss its late-stage pipeline with institutional investors and research analysts. The release identifies two central programs, CORDStrom and XPro1595, linking the event to both rare-disease commercialization planning and neuroinflammation research.
Clinical programs remain the key driver
INmune Bio describes CORDStrom as a pooled umbilical-cord-derived mesenchymal stromal cell platform being advanced toward regulatory filings for recessive dystrophic epidermolysis bullosa. The company also positions XPro1595 as a selective soluble TNF inhibitor for an adaptive Phase 2b/3 program in early Alzheimer disease.
That pipeline mix gives the stock two distinct development narratives, but both remain tied to clinical and regulatory execution. The October summit therefore matters less as a financial-results event than as a checkpoint for commercialization planning and program milestones.
Consensus target remains far above price
On September 21, 2026, MarketScreener listed a BUY mean consensus from four analysts and an average target of USD 7.000. That target lies 274.3 percent above the USD 1.87 price, making the gap between clinical expectations and the current market valuation especially visible.
A separate MarketBeat report said INmune Bio posted second-quarter 2026 EPS of USD -0.05 versus a consensus estimate of USD -0.21. The comparison shows a USD 0.16 per-share beat, although the company remains in the clinical development phase.
Stock trades below yearly high
At USD 1.87 on October 6, 2026, the stock stood 28.08 percent below its 52-week high of USD 2.60 and above its 52-week low of USD 1.09. Market capitalization was USD 49.7 million and volume reached 311,073 shares on the same Nasdaq snapshot.
For investors, the October calendar now places the Maxim summit before the next scheduled quarterly report. MarketBeat lists October 29, 2026, for the third-quarter report, with the conference call scheduled for 4:30 p.m. ET.
INMB price and market value
INmune Bio stock was last at USD 1.87 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with a 52-week range of USD 1.09 to USD 2.60. The current setup leaves the stock sensitive to clinical updates, regulatory progress and the October investor calendar.
Key facts on INmune Bio stock
- Company: INmune Bio, Inc.
- ISIN: US45782T1051
- Ticker: INMB
- Trading venue: Nasdaq
- Price (as of October 6, 2026, 4:00 p.m. ET): USD 1.87
- Market capitalization: USD 49.7 million (as of October 6, 2026)
- 52-week range: USD 1.09-2.60 (as of October 6, 2026)
- Sector / Industry: Healthcare / Biotechnology
Upcoming dates for INmune Bio stock
- October 12, 2026: Maxim Growth Summit begins
- October 29, 2026: Q3 2026 earnings report
